Senior Management

Alejandro Osorio is the Vice President of Information Technology for Vincerx. Before joining Vincerx, Alejandro was the Director of Information Technology at Acerta Pharma, a biotech company in the San Francisco Bay Area. As Head of IT, Alejandro provides leadership, strategic planning, security, budget, vendor management, and technology implementation for Vincerx and its partners.

Alejandro graduated from the University of San Francisco with a degree in Information Systems Management.

Melissa Merrick is Sr. Director, People & Culture / Head of HR for Vincerx and brings with her 10+ years of experience in leading the Human Resources function in small to mid-sized financial services, pharmaceuticals, and SaaS companies. Before joining Vincerx, Ms Merrick was the Director of Agency Integration and Onboarding at The Liberty Company where she led the integration of 6 brokerage acquisitions.

Gabriela Jairala is the Vice President of Investor Relations and Corporate Communications at Vincerx. In this role, she leads all internal and external communications, ensuring cohesive messaging and fostering strong relationships with key stakeholders. As Chief of Staff, Gabriela partners closely with the C-suite to support strategic decision-making and drive company-wide initiatives.

Karen Quarford is Vice President of Quality Operations and Compliance at Vincerx and brings with her 30 + years of quality compliance experience in small to large biotechnology companies.

Tasheda Navarro is Vice President of Clinical Operations of Vincerx.  Before joining Vincerx, Ms Navarro was the senior director of clinical operations of Acerta Pharma from March 2014 to August 2020.

Elsa Johnson is the Vice President of Program and Portfolio Management of Vincerx. Ms Johnson is the principal for Goal Management Consulting, a consulting company assisting small pharmaceutical startups in Seattle and the Bay Area develop and execute on their development plans, since December 2018.  Before that, Ms Johnson was a senior director of program management at Acerta Pharma from June 2014 to July 2018 and was part of the initial management team that led to a successful Astra Zeneca acquisition and subsequent CALQUENCE® approval.

Amy Johnson, PhD is Vice President of Medical Affairs of Vincerx.  Before Vincerx, Dr Johnson was Senior Director of Translational Research at Janssen Oncology responsible for preclinical and biomarker research in hematological malignancies.  Prior to joining industry in 2017, she had a highly productive and successful career in experimental therapeutics research at The Ohio State University, Columbus, Ohio where she was Associate Professor of Medicine with tenure.  At OSU, Amy served in many roles, including Coleader of the Leukemia Research Program and Coprincipal Investiga

Xin Huang is the Vice President of Biometrics of Vincerx. Before joining Vincerx, Dr Huang was the Head of Biostatistics at Loxo Oncology, where she established the Biostatistics and Statistical Programming department and was responsible for the oversight of all biometrics activities. Before joining Loxo, she was Director of Biostatistics at Acerta Pharma and led the statistical support for multiple hematology and solid tumor studies. Dr Huang began her career in oncology at Amgen, where she worked as statistical lead for phase 2 and phase 3 studies in the trebananib program.

Kevin Haas is the Vice President of Finance and Corporate Controller at Vincerx. Mr Haas has more than 25 years of experience in the high tech and biotech industries, 20 of which have been in the biotech industry with both large commercial and small emerging companies. Prior to Vincerx, Mr Haas held positions at Versartis, InterMune, Gilead Sciences, and Cisco Systems where he played a key role in financial management, including building finance infrastructure for product launches and leading financial integration during periods of rapid growth.

Melanie Frigault, PhD is the Vice President of Translational Medicine of Vincerx. In the year before joining Vincerx, Dr Frigault was the US head of Translational Medicine at AstraZeneca with a strategic focus on precision medicine and accelerating clinical development using novel biomarker-based endpoints in hematologic malignancies and solid tumors.